Insmed

The 2024 Top Employers Survey by Science and Science Careers ranks Insmed as the top employer in biotech, biopharma, and related industries, based on 24 characteristics like innovative leadership and employee respect. The survey, conducted by The Brighton Consulting Group, analyzed responses from 6,400 participants, primarily from North America, Europe, and Asia/Pacific Rim. Results will be published in the October 25, 2024, issue of Science and online at ScienceCareers.org.

The global peptide therapeutics market is projected to grow from $42.1B in 2023 to $56.2B by 2030, driven by technological advancements, increasing demand for targeted treatments, and the rising incidence of chronic diseases. Peptide therapeutics offer high specificity and low toxicity, making them attractive for treating conditions like cancer and diabetes. Innovations in peptide engineering and delivery systems are enhancing their efficacy and stability, expanding their therapeutic potential across various diseases.

Insmed presented positive subgroup data from the Phase 3 ASPEN study on brensocatib for non-cystic fibrosis bronchiectasis at CHEST 2024, showing consistent efficacy across subgroups. Brensocatib demonstrated reduced lung function decline and was well-tolerated. Insmed plans to file a New Drug Application for brensocatib in Q4 2024, aiming for a U.S. launch in mid-2025 and European/Japanese launches in early 2026.

BioNJ's 12th C-Suite Summit, on Oct. 10, 2024, at Bridgewater Marriott, convenes life sciences executives to discuss critical issues in innovation, policy, and market access. Featuring world-class speakers, the agenda includes topics on AI, talent, and R&D in mental health. Registration is $695 for BioNJ Members, $895 for non-members, and closed to media.

Power's AI platform simplifies patient access to clinical trials, reducing recruitment delays and enhancing patient understanding, as highlighted at DPHARM Idol Disrupt 2024.

Treprostinil Palmitil, a drug under development for rare pulmonary disorders, is expected to generate $334 mn in annual revenue by 2037 in the US. Insmed, the biopharmaceutical company developing it, reported a net loss of $749.6 mn in FY2023. The drug's risk-adjusted NPV model (rNPV) considers the risk of failure in clinical development.